These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33771113)

  • 1. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
    Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
    Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.
    Bulman ZP; Zhao M; Satlin MJ; Chen L; Kreiswirth BN; Walsh TJ; Nation RL; Li J; Tsuji BT
    Int J Antimicrob Agents; 2018 Jul; 52(1):114-118. PubMed ID: 29486233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
    Albiero J; Sy SK; Mazucheli J; Caparroz-Assef SM; Costa BB; Alves JL; Gales AC; Tognim MC
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
    Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
    Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
    Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
    Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.
    Zhao M; Bulman ZP; Lenhard JR; Satlin MJ; Kreiswirth BN; Walsh TJ; Marrocco A; Bergen PJ; Nation RL; Li J; Zhang J; Tsuji BT
    J Antimicrob Chemother; 2017 Jul; 72(7):1985-1990. PubMed ID: 28444224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of colistin resistance in carbapenemase-producing
    Meletiadis J; Paranos P; Tsala M; Pournaras S; Vourli S
    J Med Microbiol; 2022 Oct; 71(10):. PubMed ID: 36201344
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
    Kang Y; Zhou Q; Cui J
    J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae.
    Crémieux AC; Dinh A; Nordmann P; Mouton W; Tattevin P; Ghout I; Jayol A; Aimer O; Gatin L; Verdier MC; Saleh-Mghir A; Laurent F
    J Antimicrob Chemother; 2019 Sep; 74(9):2666-2675. PubMed ID: 31263884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 19. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
    Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.